betamethasone dipropionate + calcipotriol monohydrate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
betamethasone dipropionate + calcipotriol monohydrate: clinical details
Prescribing considerations
- Confirm the psoriasis type, site and formulation-specific licence.
- Review concurrent topical steroids, calcipotriol products, UV treatment and factors increasing absorption, including damaged skin, folds and occlusion.
- Safety and efficacy are not established under 18 or adequately evaluated in severe renal or hepatic impairment.
- Continued or restarted treatment should remain under medical review.
Contraindications and cautions
- Hypersensitivity to either active ingredient or an excipient
- Known calcium-metabolism disorders
- Erythrodermic or pustular psoriasis; exfoliative psoriasis is additionally contraindicated for gel and ointment
- Viral, fungal, bacterial or parasitic lesions in the treatment area; cutaneous tuberculosis
- Perioral dermatitis, atrophic skin, striae, fragile skin veins, ichthyosis, acne, rosacea, ulcers or wounds
Monitoring
- Clinical response, local irritation, infection, skin atrophy, striae and rebound or pustular worsening
- Symptoms of hypercalcaemia where exposure is excessive or extensive
- HPA-axis or systemic corticosteroid effects when absorption risk is increased
- Glycaemic control in people with diabetes if substantial systemic absorption is possible
- Visual symptoms; consider ophthalmology assessment for blurred vision or other disturbance
Clinical pharmacology
Calcipotriol suppresses keratinocyte proliferation and promotes differentiation. Betamethasone dipropionate activates glucocorticoid receptors to suppress inflammatory and immune pathways. Systemic absorption is usually low but rises with damaged skin, occlusion, extensive application or prolonged exposure.
Formulation and product differences
- Gel is suited to scalp application and licensed for scalp and mild-to-moderate non-scalp plaque psoriasis.
- Ointment is greasier and licensed for stable plaque psoriasis suitable for topical treatment.
- Foam is a flammable aerosol licensed for adult psoriasis vulgaris.
- Excipients differ and may cause local reactions; butylhydroxytoluene is present in these formulations, while gel also contains hydrogenated castor oil.
betamethasone dipropionate + calcipotriol monohydrate preparations and strengths
Gel
Route: Cutaneous
Strengths: 50 micrograms/g + 0.5 mg/g
betamethasone dipropionate + calcipotriol monohydrate interactions
Formal interaction studies have not been performed. Tell the prescriber or pharmacist about all skin treatments, supplements and phototherapy.
Other topical corticosteroids
Using another corticosteroid on the same area can increase local and systemic steroid adverse effects.
Other calcipotriol or vitamin D products
Combined exposure can increase the risk of disturbed calcium metabolism.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.